nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—CYP2D6—Vinorelbine—ovarian cancer	0.0733	0.213	CbGbCtD
Bicalutamide—CYP3A4—Topotecan—ovarian cancer	0.0662	0.192	CbGbCtD
Bicalutamide—CYP2C9—Paclitaxel—ovarian cancer	0.0563	0.164	CbGbCtD
Bicalutamide—CYP3A4—Vinorelbine—ovarian cancer	0.0466	0.135	CbGbCtD
Bicalutamide—CYP3A4—Paclitaxel—ovarian cancer	0.0328	0.0951	CbGbCtD
Bicalutamide—CYP2D6—Doxorubicin—ovarian cancer	0.0278	0.0806	CbGbCtD
Bicalutamide—CYP3A4—Docetaxel—ovarian cancer	0.0237	0.0688	CbGbCtD
Bicalutamide—CYP3A4—Doxorubicin—ovarian cancer	0.0177	0.0513	CbGbCtD
Bicalutamide—Enzalutamide—ABCB1—ovarian cancer	0.00293	1	CrCbGaD
Bicalutamide—AR—oviduct—ovarian cancer	0.00188	0.241	CbGeAlD
Bicalutamide—AR—Nuclear Receptors—PGR—ovarian cancer	0.00116	0.0192	CbGpPWpGaD
Bicalutamide—CYP2D6—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	0.00108	0.018	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptor transcription pathway—PGR—ovarian cancer	0.000916	0.0152	CbGpPWpGaD
Bicalutamide—AR—Notch-mediated HES/HEY network—PARP1—ovarian cancer	0.000909	0.0151	CbGpPWpGaD
Bicalutamide—AR—FOXA1 transcription factor network—BRCA1—ovarian cancer	0.000824	0.0137	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BARD1—ovarian cancer	0.000821	0.0136	CbGpPWpGaD
Bicalutamide—CYP3A4—Liver X Receptor Pathway—FASN—ovarian cancer	0.00079	0.0131	CbGpPWpGaD
Bicalutamide—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—ovarian cancer	0.000783	0.013	CbGpPWpGaD
Bicalutamide—AR—FOXA1 transcription factor network—SOD1—ovarian cancer	0.000781	0.013	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CD82—ovarian cancer	0.000763	0.0127	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—ATF3—ovarian cancer	0.000735	0.0122	CbGpPWpGaD
Bicalutamide—CYP3A4—Codeine and Morphine Metabolism—ABCB1—ovarian cancer	0.000709	0.0118	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—SMARCA4—ovarian cancer	0.000698	0.0116	CbGpPWpGaD
Bicalutamide—CYP2C19—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000661	0.011	CbGpPWpGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—BRCA1—ovarian cancer	0.000634	0.0105	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TOP1—ovarian cancer	0.000622	0.0103	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptors—ESR1—ovarian cancer	0.000619	0.0103	CbGpPWpGaD
Bicalutamide—CYP2D6—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000608	0.0101	CbGpPWpGaD
Bicalutamide—AR—myometrium—ovarian cancer	0.000603	0.0771	CbGeAlD
Bicalutamide—CYP2C9—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000603	0.01	CbGpPWpGaD
Bicalutamide—AR—FOXA1 transcription factor network—ESR1—ovarian cancer	0.00055	0.00914	CbGpPWpGaD
Bicalutamide—CYP2C19—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.000511	0.00848	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND2—ovarian cancer	0.000511	0.00848	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptor transcription pathway—ESR1—ovarian cancer	0.000489	0.00812	CbGpPWpGaD
Bicalutamide—AR—epithelium—ovarian cancer	0.000473	0.0605	CbGeAlD
Bicalutamide—CYP2D6—Melatonin metabolism and effects—CYP1B1—ovarian cancer	0.00047	0.0078	CbGpPWpGaD
Bicalutamide—AR—uterine cervix—ovarian cancer	0.000469	0.06	CbGeAlD
Bicalutamide—AR—Androgen receptor signaling pathway—BRCA1—ovarian cancer	0.000469	0.00779	CbGpPWpGaD
Bicalutamide—CYP3A4—Estrogen metabolism—CYP1B1—ovarian cancer	0.00045	0.00747	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MSH2—ovarian cancer	0.00045	0.00747	CbGpPWpGaD
Bicalutamide—AR—decidua—ovarian cancer	0.000447	0.0572	CbGeAlD
Bicalutamide—AR—endometrium—ovarian cancer	0.000424	0.0543	CbGeAlD
Bicalutamide—AR—Integrated Breast Cancer Pathway—SMARCA4—ovarian cancer	0.00042	0.00698	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—CCNE1—ovarian cancer	0.000411	0.00682	CbGpPWpGaD
Bicalutamide—CYP3A4—Tamoxifen metabolism—CYP1B1—ovarian cancer	0.000398	0.0066	CbGpPWpGaD
Bicalutamide—AR—gonad—ovarian cancer	0.000394	0.0503	CbGeAlD
Bicalutamide—AR—uterus—ovarian cancer	0.000391	0.05	CbGeAlD
Bicalutamide—AR—Nongenotropic Androgen signaling—MAPK3—ovarian cancer	0.000389	0.00647	CbGpPWpGaD
Bicalutamide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000389	0.00646	CbGpPWpGaD
Bicalutamide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—ovarian cancer	0.000388	0.00644	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—TERT—ovarian cancer	0.000383	0.00636	CbGpPWpGaD
Bicalutamide—AR—FOXA1 transcription factor network—CDKN1B—ovarian cancer	0.000374	0.00621	CbGpPWpGaD
Bicalutamide—AR—Nongenotropic Androgen signaling—MAPK1—ovarian cancer	0.00037	0.00615	CbGpPWpGaD
Bicalutamide—Anorexia—Paclitaxel—ovarian cancer	0.000369	0.000631	CcSEcCtD
Bicalutamide—Gastritis—Doxorubicin—ovarian cancer	0.000369	0.000631	CcSEcCtD
Bicalutamide—Muscular weakness—Doxorubicin—ovarian cancer	0.000368	0.000629	CcSEcCtD
Bicalutamide—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000368	0.000629	CcSEcCtD
Bicalutamide—Vomiting—Vinorelbine—ovarian cancer	0.000366	0.000626	CcSEcCtD
Bicalutamide—Neutropenia—Epirubicin—ovarian cancer	0.000364	0.000623	CcSEcCtD
Bicalutamide—Dysuria—Epirubicin—ovarian cancer	0.000364	0.000623	CcSEcCtD
Bicalutamide—Rash—Vinorelbine—ovarian cancer	0.000363	0.000621	CcSEcCtD
Bicalutamide—Dermatitis—Vinorelbine—ovarian cancer	0.000363	0.00062	CcSEcCtD
Bicalutamide—Headache—Vinorelbine—ovarian cancer	0.000361	0.000617	CcSEcCtD
Bicalutamide—Syncope—Docetaxel—ovarian cancer	0.000361	0.000617	CcSEcCtD
Bicalutamide—Asthma—Doxorubicin—ovarian cancer	0.00036	0.000616	CcSEcCtD
Bicalutamide—Dysphagia—Doxorubicin—ovarian cancer	0.00036	0.000616	CcSEcCtD
Bicalutamide—Influenza—Doxorubicin—ovarian cancer	0.00036	0.000616	CcSEcCtD
Bicalutamide—Pollakiuria—Epirubicin—ovarian cancer	0.00036	0.000615	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—GADD45A—ovarian cancer	0.000359	0.00596	CbGpPWpGaD
Bicalutamide—Eosinophilia—Doxorubicin—ovarian cancer	0.000357	0.00061	CcSEcCtD
Bicalutamide—AR—Notch-mediated HES/HEY network—CDKN1B—ovarian cancer	0.000355	0.00589	CbGpPWpGaD
Bicalutamide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000354	0.00589	CbGpPWpGaD
Bicalutamide—Weight increased—Epirubicin—ovarian cancer	0.000354	0.000606	CcSEcCtD
Bicalutamide—Loss of consciousness—Docetaxel—ovarian cancer	0.000353	0.000604	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000353	0.000603	CcSEcCtD
Bicalutamide—Weight decreased—Epirubicin—ovarian cancer	0.000352	0.000602	CcSEcCtD
Bicalutamide—AR—female reproductive system—ovarian cancer	0.000352	0.045	CbGeAlD
Bicalutamide—Hyperglycaemia—Epirubicin—ovarian cancer	0.000351	0.000601	CcSEcCtD
Bicalutamide—Cough—Docetaxel—ovarian cancer	0.000351	0.0006	CcSEcCtD
Bicalutamide—Angina pectoris—Doxorubicin—ovarian cancer	0.000351	0.0006	CcSEcCtD
Bicalutamide—Insomnia—Paclitaxel—ovarian cancer	0.00035	0.000599	CcSEcCtD
Bicalutamide—Pneumonia—Epirubicin—ovarian cancer	0.000349	0.000597	CcSEcCtD
Bicalutamide—Paraesthesia—Paclitaxel—ovarian cancer	0.000348	0.000595	CcSEcCtD
Bicalutamide—Hypertension—Docetaxel—ovarian cancer	0.000347	0.000594	CcSEcCtD
Bicalutamide—Bronchitis—Doxorubicin—ovarian cancer	0.000346	0.000592	CcSEcCtD
Bicalutamide—Dyspnoea—Paclitaxel—ovarian cancer	0.000345	0.00059	CcSEcCtD
Bicalutamide—Somnolence—Paclitaxel—ovarian cancer	0.000344	0.000589	CcSEcCtD
Bicalutamide—Myalgia—Docetaxel—ovarian cancer	0.000342	0.000586	CcSEcCtD
Bicalutamide—Chest pain—Docetaxel—ovarian cancer	0.000342	0.000586	CcSEcCtD
Bicalutamide—Nausea—Vinorelbine—ovarian cancer	0.000342	0.000585	CcSEcCtD
Bicalutamide—Dyspepsia—Paclitaxel—ovarian cancer	0.000341	0.000583	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Epirubicin—ovarian cancer	0.00034	0.000582	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.00034	0.000581	CcSEcCtD
Bicalutamide—Jaundice—Epirubicin—ovarian cancer	0.000338	0.000579	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—ESR1—ovarian cancer	0.000338	0.00561	CbGpPWpGaD
Bicalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000338	0.00561	CbGpPWpGaD
Bicalutamide—Urinary tract infection—Epirubicin—ovarian cancer	0.000337	0.000577	CcSEcCtD
Bicalutamide—Conjunctivitis—Epirubicin—ovarian cancer	0.000337	0.000577	CcSEcCtD
Bicalutamide—Dysuria—Doxorubicin—ovarian cancer	0.000337	0.000576	CcSEcCtD
Bicalutamide—Neutropenia—Doxorubicin—ovarian cancer	0.000337	0.000576	CcSEcCtD
Bicalutamide—Decreased appetite—Paclitaxel—ovarian cancer	0.000337	0.000576	CcSEcCtD
Bicalutamide—Dry mouth—Docetaxel—ovarian cancer	0.000335	0.000573	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000334	0.000572	CcSEcCtD
Bicalutamide—Fatigue—Paclitaxel—ovarian cancer	0.000334	0.000571	CcSEcCtD
Bicalutamide—Sweating—Epirubicin—ovarian cancer	0.000333	0.000569	CcSEcCtD
Bicalutamide—Pollakiuria—Doxorubicin—ovarian cancer	0.000333	0.000569	CcSEcCtD
Bicalutamide—Pain—Paclitaxel—ovarian cancer	0.000331	0.000566	CcSEcCtD
Bicalutamide—Constipation—Paclitaxel—ovarian cancer	0.000331	0.000566	CcSEcCtD
Bicalutamide—Haematuria—Epirubicin—ovarian cancer	0.000331	0.000566	CcSEcCtD
Bicalutamide—Confusional state—Docetaxel—ovarian cancer	0.000331	0.000566	CcSEcCtD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.00033	0.00549	CbGpPWpGaD
Bicalutamide—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000328	0.000561	CcSEcCtD
Bicalutamide—Oedema—Docetaxel—ovarian cancer	0.000328	0.000561	CcSEcCtD
Bicalutamide—Weight increased—Doxorubicin—ovarian cancer	0.000328	0.000561	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CHEK2—ovarian cancer	0.000328	0.00544	CbGpPWpGaD
Bicalutamide—Epistaxis—Epirubicin—ovarian cancer	0.000327	0.00056	CcSEcCtD
Bicalutamide—CYP3A4—Irinotecan Pathway—APC—ovarian cancer	0.000326	0.00542	CbGpPWpGaD
Bicalutamide—Infection—Docetaxel—ovarian cancer	0.000326	0.000558	CcSEcCtD
Bicalutamide—Weight decreased—Doxorubicin—ovarian cancer	0.000326	0.000557	CcSEcCtD
Bicalutamide—Sinusitis—Epirubicin—ovarian cancer	0.000326	0.000557	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—CAV1—ovarian cancer	0.000325	0.0054	CbGpPWpGaD
Bicalutamide—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000325	0.000556	CcSEcCtD
Bicalutamide—Pneumonia—Doxorubicin—ovarian cancer	0.000323	0.000552	CcSEcCtD
Bicalutamide—Shock—Docetaxel—ovarian cancer	0.000323	0.000552	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—APC—ovarian cancer	0.000322	0.00535	CbGpPWpGaD
Bicalutamide—Nervous system disorder—Docetaxel—ovarian cancer	0.000322	0.00055	CcSEcCtD
Bicalutamide—AR—Nongenotropic Androgen signaling—PIK3CA—ovarian cancer	0.000321	0.00534	CbGpPWpGaD
Bicalutamide—Thrombocytopenia—Docetaxel—ovarian cancer	0.000321	0.00055	CcSEcCtD
Bicalutamide—AR—female gonad—ovarian cancer	0.00032	0.0409	CbGeAlD
Bicalutamide—Feeling abnormal—Paclitaxel—ovarian cancer	0.000319	0.000546	CcSEcCtD
Bicalutamide—Skin disorder—Docetaxel—ovarian cancer	0.000319	0.000545	CcSEcCtD
Bicalutamide—AR—vagina—ovarian cancer	0.000318	0.0407	CbGeAlD
Bicalutamide—AR—Generic Transcription Pathway—NR5A1—ovarian cancer	0.000318	0.00528	CbGpPWpGaD
Bicalutamide—Bradycardia—Epirubicin—ovarian cancer	0.000317	0.000542	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000317	0.000542	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000315	0.000538	CcSEcCtD
Bicalutamide—Haemoglobin—Epirubicin—ovarian cancer	0.000313	0.000536	CcSEcCtD
Bicalutamide—Jaundice—Doxorubicin—ovarian cancer	0.000313	0.000535	CcSEcCtD
Bicalutamide—Anorexia—Docetaxel—ovarian cancer	0.000313	0.000535	CcSEcCtD
Bicalutamide—Rhinitis—Epirubicin—ovarian cancer	0.000312	0.000534	CcSEcCtD
Bicalutamide—Urinary tract infection—Doxorubicin—ovarian cancer	0.000312	0.000534	CcSEcCtD
Bicalutamide—Conjunctivitis—Doxorubicin—ovarian cancer	0.000312	0.000534	CcSEcCtD
Bicalutamide—Haemorrhage—Epirubicin—ovarian cancer	0.000312	0.000533	CcSEcCtD
Bicalutamide—Pharyngitis—Epirubicin—ovarian cancer	0.000309	0.000529	CcSEcCtD
Bicalutamide—Sweating—Doxorubicin—ovarian cancer	0.000308	0.000527	CcSEcCtD
Bicalutamide—Urinary tract disorder—Epirubicin—ovarian cancer	0.000308	0.000526	CcSEcCtD
Bicalutamide—Urticaria—Paclitaxel—ovarian cancer	0.000308	0.000526	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BRCA1—ovarian cancer	0.000307	0.0051	CbGpPWpGaD
Bicalutamide—Oedema peripheral—Epirubicin—ovarian cancer	0.000307	0.000525	CcSEcCtD
Bicalutamide—Haematuria—Doxorubicin—ovarian cancer	0.000306	0.000524	CcSEcCtD
Bicalutamide—Abdominal pain—Paclitaxel—ovarian cancer	0.000306	0.000523	CcSEcCtD
Bicalutamide—Body temperature increased—Paclitaxel—ovarian cancer	0.000306	0.000523	CcSEcCtD
Bicalutamide—Urethral disorder—Epirubicin—ovarian cancer	0.000305	0.000522	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000304	0.000519	CcSEcCtD
Bicalutamide—Epistaxis—Doxorubicin—ovarian cancer	0.000303	0.000518	CcSEcCtD
Bicalutamide—Sinusitis—Doxorubicin—ovarian cancer	0.000301	0.000515	CcSEcCtD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000301	0.005	CbGpPWpGaD
Bicalutamide—Visual impairment—Epirubicin—ovarian cancer	0.0003	0.000514	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000299	0.000511	CcSEcCtD
Bicalutamide—AR—Nongenotropic Androgen signaling—HRAS—ovarian cancer	0.000297	0.00494	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—GADD45A—ovarian cancer	0.000297	0.00494	CbGpPWpGaD
Bicalutamide—Insomnia—Docetaxel—ovarian cancer	0.000297	0.000508	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—ovarian cancer	0.000297	0.00493	CbGpPWpGaD
Bicalutamide—Paraesthesia—Docetaxel—ovarian cancer	0.000295	0.000504	CcSEcCtD
Bicalutamide—CYP2C19—vagina—ovarian cancer	0.000295	0.0377	CbGeAlD
Bicalutamide—Bradycardia—Doxorubicin—ovarian cancer	0.000294	0.000502	CcSEcCtD
Bicalutamide—Dyspnoea—Docetaxel—ovarian cancer	0.000293	0.0005	CcSEcCtD
Bicalutamide—AR—Notch-mediated HES/HEY network—STAT3—ovarian cancer	0.000292	0.00485	CbGpPWpGaD
Bicalutamide—Somnolence—Docetaxel—ovarian cancer	0.000292	0.000499	CcSEcCtD
Bicalutamide—Haemoglobin—Doxorubicin—ovarian cancer	0.00029	0.000496	CcSEcCtD
Bicalutamide—Cardiac disorder—Epirubicin—ovarian cancer	0.000289	0.000495	CcSEcCtD
Bicalutamide—Rhinitis—Doxorubicin—ovarian cancer	0.000289	0.000494	CcSEcCtD
Bicalutamide—Dyspepsia—Docetaxel—ovarian cancer	0.000289	0.000494	CcSEcCtD
Bicalutamide—Haemorrhage—Doxorubicin—ovarian cancer	0.000288	0.000493	CcSEcCtD
Bicalutamide—Pharyngitis—Doxorubicin—ovarian cancer	0.000286	0.000489	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—ovarian cancer	0.000286	0.00474	CbGpPWpGaD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000285	0.00474	CbGpPWpGaD
Bicalutamide—Decreased appetite—Docetaxel—ovarian cancer	0.000285	0.000488	CcSEcCtD
Bicalutamide—Hypersensitivity—Paclitaxel—ovarian cancer	0.000285	0.000488	CcSEcCtD
Bicalutamide—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000285	0.000487	CcSEcCtD
Bicalutamide—Oedema peripheral—Doxorubicin—ovarian cancer	0.000284	0.000486	CcSEcCtD
Bicalutamide—AR—testis—ovarian cancer	0.000284	0.0363	CbGeAlD
Bicalutamide—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000283	0.000485	CcSEcCtD
Bicalutamide—Fatigue—Docetaxel—ovarian cancer	0.000283	0.000484	CcSEcCtD
Bicalutamide—Angiopathy—Epirubicin—ovarian cancer	0.000283	0.000483	CcSEcCtD
Bicalutamide—Urethral disorder—Doxorubicin—ovarian cancer	0.000283	0.000483	CcSEcCtD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000282	0.00468	CbGpPWpGaD
Bicalutamide—Immune system disorder—Epirubicin—ovarian cancer	0.000281	0.000481	CcSEcCtD
Bicalutamide—Mediastinal disorder—Epirubicin—ovarian cancer	0.000281	0.00048	CcSEcCtD
Bicalutamide—Constipation—Docetaxel—ovarian cancer	0.000281	0.00048	CcSEcCtD
Bicalutamide—Pain—Docetaxel—ovarian cancer	0.000281	0.00048	CcSEcCtD
Bicalutamide—Chills—Epirubicin—ovarian cancer	0.00028	0.000478	CcSEcCtD
Bicalutamide—Arrhythmia—Epirubicin—ovarian cancer	0.000278	0.000476	CcSEcCtD
Bicalutamide—Visual impairment—Doxorubicin—ovarian cancer	0.000278	0.000475	CcSEcCtD
Bicalutamide—Asthenia—Paclitaxel—ovarian cancer	0.000278	0.000475	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—BRCA2—ovarian cancer	0.000278	0.00461	CbGpPWpGaD
Bicalutamide—Alopecia—Epirubicin—ovarian cancer	0.000275	0.000471	CcSEcCtD
Bicalutamide—AR—Coregulation of Androgen receptor activity—CCND1—ovarian cancer	0.000275	0.00456	CbGpPWpGaD
Bicalutamide—Pruritus—Paclitaxel—ovarian cancer	0.000274	0.000469	CcSEcCtD
Bicalutamide—Mental disorder—Epirubicin—ovarian cancer	0.000273	0.000467	CcSEcCtD
Bicalutamide—AR—Coregulation of Androgen receptor activity—CTNNB1—ovarian cancer	0.000272	0.00452	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CHEK2—ovarian cancer	0.000272	0.00451	CbGpPWpGaD
Bicalutamide—Malnutrition—Epirubicin—ovarian cancer	0.000271	0.000464	CcSEcCtD
Bicalutamide—Feeling abnormal—Docetaxel—ovarian cancer	0.00027	0.000463	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000268	0.000459	CcSEcCtD
Bicalutamide—Cardiac disorder—Doxorubicin—ovarian cancer	0.000268	0.000458	CcSEcCtD
Bicalutamide—Flatulence—Epirubicin—ovarian cancer	0.000267	0.000457	CcSEcCtD
Bicalutamide—Tension—Epirubicin—ovarian cancer	0.000266	0.000455	CcSEcCtD
Bicalutamide—Diarrhoea—Paclitaxel—ovarian cancer	0.000265	0.000453	CcSEcCtD
Bicalutamide—Nervousness—Epirubicin—ovarian cancer	0.000263	0.000451	CcSEcCtD
Bicalutamide—AR—Nongenotropic Androgen signaling—AKT1—ovarian cancer	0.000263	0.00436	CbGpPWpGaD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000263	0.00436	CbGpPWpGaD
Bicalutamide—Back pain—Epirubicin—ovarian cancer	0.000262	0.000449	CcSEcCtD
Bicalutamide—Angiopathy—Doxorubicin—ovarian cancer	0.000262	0.000447	CcSEcCtD
Bicalutamide—Muscle spasms—Epirubicin—ovarian cancer	0.000261	0.000446	CcSEcCtD
Bicalutamide—Immune system disorder—Doxorubicin—ovarian cancer	0.00026	0.000445	CcSEcCtD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.00026	0.00432	CbGpPWpGaD
Bicalutamide—Mediastinal disorder—Doxorubicin—ovarian cancer	0.00026	0.000444	CcSEcCtD
Bicalutamide—Abdominal pain—Docetaxel—ovarian cancer	0.000259	0.000444	CcSEcCtD
Bicalutamide—Body temperature increased—Docetaxel—ovarian cancer	0.000259	0.000444	CcSEcCtD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000259	0.0043	CbGpPWpGaD
Bicalutamide—Chills—Doxorubicin—ovarian cancer	0.000259	0.000442	CcSEcCtD
Bicalutamide—Arrhythmia—Doxorubicin—ovarian cancer	0.000258	0.00044	CcSEcCtD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000257	0.00427	CbGpPWpGaD
Bicalutamide—Dizziness—Paclitaxel—ovarian cancer	0.000256	0.000438	CcSEcCtD
Bicalutamide—Alopecia—Doxorubicin—ovarian cancer	0.000255	0.000436	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—BRCA1—ovarian cancer	0.000255	0.00423	CbGpPWpGaD
Bicalutamide—Mental disorder—Doxorubicin—ovarian cancer	0.000253	0.000432	CcSEcCtD
Bicalutamide—CYP2C9—female reproductive system—ovarian cancer	0.000253	0.0323	CbGeAlD
Bicalutamide—Malnutrition—Doxorubicin—ovarian cancer	0.000251	0.000429	CcSEcCtD
Bicalutamide—Anaemia—Epirubicin—ovarian cancer	0.000251	0.000429	CcSEcCtD
Bicalutamide—Flatulence—Doxorubicin—ovarian cancer	0.000247	0.000423	CcSEcCtD
Bicalutamide—Tension—Doxorubicin—ovarian cancer	0.000246	0.000421	CcSEcCtD
Bicalutamide—Vomiting—Paclitaxel—ovarian cancer	0.000246	0.000421	CcSEcCtD
Bicalutamide—Rash—Paclitaxel—ovarian cancer	0.000244	0.000418	CcSEcCtD
Bicalutamide—Dermatitis—Paclitaxel—ovarian cancer	0.000244	0.000417	CcSEcCtD
Bicalutamide—Nervousness—Doxorubicin—ovarian cancer	0.000244	0.000417	CcSEcCtD
Bicalutamide—Syncope—Epirubicin—ovarian cancer	0.000243	0.000416	CcSEcCtD
Bicalutamide—Back pain—Doxorubicin—ovarian cancer	0.000243	0.000415	CcSEcCtD
Bicalutamide—Headache—Paclitaxel—ovarian cancer	0.000243	0.000415	CcSEcCtD
Bicalutamide—Hypersensitivity—Docetaxel—ovarian cancer	0.000242	0.000414	CcSEcCtD
Bicalutamide—Muscle spasms—Doxorubicin—ovarian cancer	0.000241	0.000413	CcSEcCtD
Bicalutamide—Loss of consciousness—Epirubicin—ovarian cancer	0.000238	0.000408	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—ovarian cancer	0.000237	0.00394	CbGpPWpGaD
Bicalutamide—Cough—Epirubicin—ovarian cancer	0.000237	0.000405	CcSEcCtD
Bicalutamide—Asthenia—Docetaxel—ovarian cancer	0.000235	0.000403	CcSEcCtD
Bicalutamide—Hypertension—Epirubicin—ovarian cancer	0.000234	0.0004	CcSEcCtD
Bicalutamide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000234	0.00388	CbGpPWpGaD
Bicalutamide—Pruritus—Docetaxel—ovarian cancer	0.000232	0.000397	CcSEcCtD
Bicalutamide—Anaemia—Doxorubicin—ovarian cancer	0.000232	0.000397	CcSEcCtD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000231	0.00384	CbGpPWpGaD
Bicalutamide—Myalgia—Epirubicin—ovarian cancer	0.000231	0.000395	CcSEcCtD
Bicalutamide—Chest pain—Epirubicin—ovarian cancer	0.000231	0.000395	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—BRCA2—ovarian cancer	0.00023	0.00382	CbGpPWpGaD
Bicalutamide—Anxiety—Epirubicin—ovarian cancer	0.00023	0.000394	CcSEcCtD
Bicalutamide—Nausea—Paclitaxel—ovarian cancer	0.00023	0.000393	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000229	0.000392	CcSEcCtD
Bicalutamide—Dry mouth—Epirubicin—ovarian cancer	0.000226	0.000386	CcSEcCtD
Bicalutamide—Syncope—Doxorubicin—ovarian cancer	0.000225	0.000385	CcSEcCtD
Bicalutamide—Diarrhoea—Docetaxel—ovarian cancer	0.000225	0.000384	CcSEcCtD
Bicalutamide—Confusional state—Epirubicin—ovarian cancer	0.000223	0.000382	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ABCB1—ovarian cancer	0.000223	0.0037	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CCNE1—ovarian cancer	0.000223	0.0037	CbGpPWpGaD
Bicalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000223	0.0037	CbGpPWpGaD
Bicalutamide—Oedema—Epirubicin—ovarian cancer	0.000221	0.000379	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—ovarian cancer	0.000221	0.00367	CbGpPWpGaD
Bicalutamide—Loss of consciousness—Doxorubicin—ovarian cancer	0.000221	0.000377	CcSEcCtD
Bicalutamide—Infection—Epirubicin—ovarian cancer	0.00022	0.000376	CcSEcCtD
Bicalutamide—Cough—Doxorubicin—ovarian cancer	0.000219	0.000375	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—ovarian cancer	0.000219	0.00364	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TYMS—ovarian cancer	0.000219	0.00364	CbGpPWpGaD
Bicalutamide—Shock—Epirubicin—ovarian cancer	0.000218	0.000372	CcSEcCtD
Bicalutamide—Nervous system disorder—Epirubicin—ovarian cancer	0.000217	0.000371	CcSEcCtD
Bicalutamide—Dizziness—Docetaxel—ovarian cancer	0.000217	0.000371	CcSEcCtD
Bicalutamide—Thrombocytopenia—Epirubicin—ovarian cancer	0.000217	0.000371	CcSEcCtD
Bicalutamide—Hypertension—Doxorubicin—ovarian cancer	0.000217	0.000371	CcSEcCtD
Bicalutamide—Skin disorder—Epirubicin—ovarian cancer	0.000215	0.000368	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—ovarian cancer	0.000215	0.00357	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—WDR77—ovarian cancer	0.000215	0.00356	CbGpPWpGaD
Bicalutamide—Hyperhidrosis—Epirubicin—ovarian cancer	0.000214	0.000366	CcSEcCtD
Bicalutamide—Myalgia—Doxorubicin—ovarian cancer	0.000214	0.000365	CcSEcCtD
Bicalutamide—Chest pain—Doxorubicin—ovarian cancer	0.000214	0.000365	CcSEcCtD
Bicalutamide—Anxiety—Doxorubicin—ovarian cancer	0.000213	0.000364	CcSEcCtD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000213	0.00354	CbGpPWpGaD
Bicalutamide—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000212	0.00353	CbGpPWpGaD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000212	0.000363	CcSEcCtD
Bicalutamide—Anorexia—Epirubicin—ovarian cancer	0.000211	0.000361	CcSEcCtD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000211	0.0035	CbGpPWpGaD
Bicalutamide—Dry mouth—Doxorubicin—ovarian cancer	0.000209	0.000357	CcSEcCtD
Bicalutamide—Vomiting—Docetaxel—ovarian cancer	0.000209	0.000357	CcSEcCtD
Bicalutamide—Rash—Docetaxel—ovarian cancer	0.000207	0.000354	CcSEcCtD
Bicalutamide—Dermatitis—Docetaxel—ovarian cancer	0.000207	0.000354	CcSEcCtD
Bicalutamide—Confusional state—Doxorubicin—ovarian cancer	0.000207	0.000353	CcSEcCtD
Bicalutamide—AR—lymph node—ovarian cancer	0.000206	0.0263	CbGeAlD
Bicalutamide—Headache—Docetaxel—ovarian cancer	0.000206	0.000352	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—ESR1—ovarian cancer	0.000205	0.00341	CbGpPWpGaD
Bicalutamide—Oedema—Doxorubicin—ovarian cancer	0.000205	0.00035	CcSEcCtD
Bicalutamide—Infection—Doxorubicin—ovarian cancer	0.000204	0.000348	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—CCND1—ovarian cancer	0.000203	0.00337	CbGpPWpGaD
Bicalutamide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000202	0.000345	CcSEcCtD
Bicalutamide—Shock—Doxorubicin—ovarian cancer	0.000202	0.000345	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—CTNNB1—ovarian cancer	0.000201	0.00334	CbGpPWpGaD
Bicalutamide—Nervous system disorder—Doxorubicin—ovarian cancer	0.000201	0.000344	CcSEcCtD
Bicalutamide—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000201	0.000343	CcSEcCtD
Bicalutamide—Insomnia—Epirubicin—ovarian cancer	0.0002	0.000342	CcSEcCtD
Bicalutamide—Skin disorder—Doxorubicin—ovarian cancer	0.000199	0.00034	CcSEcCtD
Bicalutamide—Paraesthesia—Epirubicin—ovarian cancer	0.000199	0.00034	CcSEcCtD
Bicalutamide—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000198	0.000339	CcSEcCtD
Bicalutamide—Dyspnoea—Epirubicin—ovarian cancer	0.000197	0.000338	CcSEcCtD
Bicalutamide—Somnolence—Epirubicin—ovarian cancer	0.000197	0.000337	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—PTEN—ovarian cancer	0.000196	0.00326	CbGpPWpGaD
Bicalutamide—Anorexia—Doxorubicin—ovarian cancer	0.000195	0.000334	CcSEcCtD
Bicalutamide—Nausea—Docetaxel—ovarian cancer	0.000195	0.000333	CcSEcCtD
Bicalutamide—Dyspepsia—Epirubicin—ovarian cancer	0.000195	0.000333	CcSEcCtD
Bicalutamide—CYP3A4—female reproductive system—ovarian cancer	0.000193	0.0246	CbGeAlD
Bicalutamide—Decreased appetite—Epirubicin—ovarian cancer	0.000192	0.000329	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000191	0.000327	CcSEcCtD
Bicalutamide—Fatigue—Epirubicin—ovarian cancer	0.000191	0.000326	CcSEcCtD
Bicalutamide—CYP2D6—female reproductive system—ovarian cancer	0.00019	0.0242	CbGeAlD
Bicalutamide—Pain—Epirubicin—ovarian cancer	0.000189	0.000324	CcSEcCtD
Bicalutamide—Constipation—Epirubicin—ovarian cancer	0.000189	0.000324	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000187	0.000319	CcSEcCtD
Bicalutamide—Insomnia—Doxorubicin—ovarian cancer	0.000185	0.000317	CcSEcCtD
Bicalutamide—Paraesthesia—Doxorubicin—ovarian cancer	0.000184	0.000315	CcSEcCtD
Bicalutamide—Dyspnoea—Doxorubicin—ovarian cancer	0.000183	0.000312	CcSEcCtD
Bicalutamide—Feeling abnormal—Epirubicin—ovarian cancer	0.000182	0.000312	CcSEcCtD
Bicalutamide—Somnolence—Doxorubicin—ovarian cancer	0.000182	0.000311	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—YAP1—ovarian cancer	0.000181	0.00301	CbGpPWpGaD
Bicalutamide—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000181	0.00031	CcSEcCtD
Bicalutamide—Dyspepsia—Doxorubicin—ovarian cancer	0.00018	0.000308	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CDH1—ovarian cancer	0.000178	0.00296	CbGpPWpGaD
Bicalutamide—Decreased appetite—Doxorubicin—ovarian cancer	0.000178	0.000305	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—ovarian cancer	0.000177	0.00295	CbGpPWpGaD
Bicalutamide—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000177	0.000302	CcSEcCtD
Bicalutamide—Fatigue—Doxorubicin—ovarian cancer	0.000177	0.000302	CcSEcCtD
Bicalutamide—Urticaria—Epirubicin—ovarian cancer	0.000176	0.000301	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—ovarian cancer	0.000176	0.00292	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—STAT3—ovarian cancer	0.000175	0.00291	CbGpPWpGaD
Bicalutamide—Constipation—Doxorubicin—ovarian cancer	0.000175	0.0003	CcSEcCtD
Bicalutamide—Pain—Doxorubicin—ovarian cancer	0.000175	0.0003	CcSEcCtD
Bicalutamide—Abdominal pain—Epirubicin—ovarian cancer	0.000175	0.000299	CcSEcCtD
Bicalutamide—Body temperature increased—Epirubicin—ovarian cancer	0.000175	0.000299	CcSEcCtD
Bicalutamide—CYP2D6—female gonad—ovarian cancer	0.000172	0.0221	CbGeAlD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000172	0.00285	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ESR1—ovarian cancer	0.00017	0.00282	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000169	0.00281	CbGpPWpGaD
Bicalutamide—Feeling abnormal—Doxorubicin—ovarian cancer	0.000169	0.000289	CcSEcCtD
Bicalutamide—AR—Gene Expression—TTF1—ovarian cancer	0.000168	0.0028	CbGpPWpGaD
Bicalutamide—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000168	0.000286	CcSEcCtD
Bicalutamide—Hypersensitivity—Epirubicin—ovarian cancer	0.000163	0.000279	CcSEcCtD
Bicalutamide—Urticaria—Doxorubicin—ovarian cancer	0.000163	0.000278	CcSEcCtD
Bicalutamide—Abdominal pain—Doxorubicin—ovarian cancer	0.000162	0.000277	CcSEcCtD
Bicalutamide—Body temperature increased—Doxorubicin—ovarian cancer	0.000162	0.000277	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—APC—ovarian cancer	0.000161	0.00267	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—EGFR—ovarian cancer	0.000159	0.00265	CbGpPWpGaD
Bicalutamide—Asthenia—Epirubicin—ovarian cancer	0.000159	0.000272	CcSEcCtD
Bicalutamide—AR—Generic Transcription Pathway—PGR—ovarian cancer	0.000158	0.00263	CbGpPWpGaD
Bicalutamide—Pruritus—Epirubicin—ovarian cancer	0.000157	0.000268	CcSEcCtD
Bicalutamide—CYP2D6—testis—ovarian cancer	0.000153	0.0196	CbGeAlD
Bicalutamide—AR—Gene Expression—NR5A1—ovarian cancer	0.000153	0.00254	CbGpPWpGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—AKT1—ovarian cancer	0.000153	0.00254	CbGpPWpGaD
Bicalutamide—Diarrhoea—Epirubicin—ovarian cancer	0.000151	0.000259	CcSEcCtD
Bicalutamide—Hypersensitivity—Doxorubicin—ovarian cancer	0.000151	0.000258	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MTOR—ovarian cancer	0.000149	0.00247	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—PARP1—ovarian cancer	0.000147	0.00244	CbGpPWpGaD
Bicalutamide—Asthenia—Doxorubicin—ovarian cancer	0.000147	0.000251	CcSEcCtD
Bicalutamide—Dizziness—Epirubicin—ovarian cancer	0.000146	0.00025	CcSEcCtD
Bicalutamide—Pruritus—Doxorubicin—ovarian cancer	0.000145	0.000248	CcSEcCtD
Bicalutamide—Vomiting—Epirubicin—ovarian cancer	0.000141	0.000241	CcSEcCtD
Bicalutamide—Diarrhoea—Doxorubicin—ovarian cancer	0.00014	0.00024	CcSEcCtD
Bicalutamide—Rash—Epirubicin—ovarian cancer	0.00014	0.000239	CcSEcCtD
Bicalutamide—Dermatitis—Epirubicin—ovarian cancer	0.000139	0.000238	CcSEcCtD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000139	0.00231	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	0.000139	0.00231	CbGpPWpGaD
Bicalutamide—Headache—Epirubicin—ovarian cancer	0.000139	0.000237	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CASP3—ovarian cancer	0.000137	0.00227	CbGpPWpGaD
Bicalutamide—Dizziness—Doxorubicin—ovarian cancer	0.000135	0.000232	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—CASP3—ovarian cancer	0.000133	0.00221	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CCND1—ovarian cancer	0.000133	0.00221	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CTNNB1—ovarian cancer	0.000132	0.00219	CbGpPWpGaD
Bicalutamide—Nausea—Epirubicin—ovarian cancer	0.000131	0.000225	CcSEcCtD
Bicalutamide—Vomiting—Doxorubicin—ovarian cancer	0.00013	0.000223	CcSEcCtD
Bicalutamide—Rash—Doxorubicin—ovarian cancer	0.000129	0.000221	CcSEcCtD
Bicalutamide—Dermatitis—Doxorubicin—ovarian cancer	0.000129	0.000221	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—PTEN—ovarian cancer	0.000128	0.00213	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	0.000128	0.00213	CbGpPWpGaD
Bicalutamide—Headache—Doxorubicin—ovarian cancer	0.000128	0.000219	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ERBB2—ovarian cancer	0.000125	0.00207	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP1B1—ovarian cancer	0.000123	0.00204	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	0.000122	0.00202	CbGpPWpGaD
Bicalutamide—Nausea—Doxorubicin—ovarian cancer	0.000122	0.000208	CcSEcCtD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000121	0.00201	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—VEGFA—ovarian cancer	0.000116	0.00193	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1B—ovarian cancer	0.000116	0.00192	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CASP3—ovarian cancer	0.000113	0.00188	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP1B1—ovarian cancer	0.000113	0.00188	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	0.000113	0.00188	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—AKT1—ovarian cancer	0.000113	0.00188	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	0.000112	0.00186	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000112	0.00185	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000111	0.00184	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—ovarian cancer	0.00011	0.00183	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—ovarian cancer	0.000109	0.00181	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MYC—ovarian cancer	0.000107	0.00177	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	0.000106	0.00177	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MAPK1—ovarian cancer	0.000104	0.00173	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—EGFR—ovarian cancer	0.000104	0.00173	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—KRAS—ovarian cancer	9.86e-05	0.00164	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	9.61e-05	0.0016	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	9.48e-05	0.00157	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	9.09e-05	0.00151	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	8.84e-05	0.00147	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—TP53—ovarian cancer	8.76e-05	0.00146	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—YAP1—ovarian cancer	8.72e-05	0.00145	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	8.65e-05	0.00144	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	8.65e-05	0.00144	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	8.64e-05	0.00144	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—ESR1—ovarian cancer	8.44e-05	0.0014	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	8.17e-05	0.00136	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—IL6—ovarian cancer	7.82e-05	0.0013	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PGR—ovarian cancer	7.61e-05	0.00126	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	7.51e-05	0.00125	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NME2—ovarian cancer	7.49e-05	0.00124	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—AKT1—ovarian cancer	7.4e-05	0.00123	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	7.39e-05	0.00123	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	7.29e-05	0.00121	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	7.26e-05	0.00121	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PARP1—ovarian cancer	7.08e-05	0.00118	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NME2—ovarian cancer	6.89e-05	0.00115	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NME2—ovarian cancer	6.83e-05	0.00114	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	6.36e-05	0.00106	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	6.13e-05	0.00102	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	5.8e-05	0.000963	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PPP2R1A—ovarian cancer	5.74e-05	0.000954	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	5.18e-05	0.000861	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYTB—ovarian cancer	4.83e-05	0.000802	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	4.73e-05	0.000785	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.72e-05	0.000784	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NME2—ovarian cancer	4.51e-05	0.000749	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYTB—ovarian cancer	4.44e-05	0.000738	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYTB—ovarian cancer	4.4e-05	0.000731	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—MYC—ovarian cancer	4.39e-05	0.00073	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	4.3e-05	0.000715	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PPP1CC—ovarian cancer	4.22e-05	0.000701	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—BRIP1—ovarian cancer	4.22e-05	0.000701	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—ESR1—ovarian cancer	4.07e-05	0.000675	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PPP1CC—ovarian cancer	3.88e-05	0.000645	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—BRIP1—ovarian cancer	3.88e-05	0.000645	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PPP1CC—ovarian cancer	3.85e-05	0.000639	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—BRIP1—ovarian cancer	3.85e-05	0.000639	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.08e-05	0.000511	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYTB—ovarian cancer	2.9e-05	0.000482	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—YAP1—ovarian cancer	2.83e-05	0.00047	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.8e-05	0.000466	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.8e-05	0.000465	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—YAP1—ovarian cancer	2.6e-05	0.000433	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—YAP1—ovarian cancer	2.58e-05	0.000429	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.55e-05	0.000424	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PPP1CC—ovarian cancer	2.54e-05	0.000422	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—BRIP1—ovarian cancer	2.54e-05	0.000422	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.46e-05	0.000409	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—FASN—ovarian cancer	2.31e-05	0.000383	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SLC5A5—ovarian cancer	2.27e-05	0.000377	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.25e-05	0.000373	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SLC2A1—ovarian cancer	2.19e-05	0.000364	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—MAPK3—ovarian cancer	2.17e-05	0.000361	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.15e-05	0.000357	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—FASN—ovarian cancer	2.12e-05	0.000353	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—MYC—ovarian cancer	2.11e-05	0.000351	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—FASN—ovarian cancer	2.1e-05	0.00035	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP1B1—ovarian cancer	2.1e-05	0.000349	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SLC5A5—ovarian cancer	2.09e-05	0.000347	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SLC5A5—ovarian cancer	2.07e-05	0.000344	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SLC2A1—ovarian cancer	2.02e-05	0.000335	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SLC2A1—ovarian cancer	2e-05	0.000332	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.96e-05	0.000325	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.93e-05	0.000321	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.92e-05	0.000318	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PPP2R1A—ovarian cancer	1.86e-05	0.00031	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.86e-05	0.000308	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—ABCB1—ovarian cancer	1.73e-05	0.000288	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.71e-05	0.000285	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—YAP1—ovarian cancer	1.7e-05	0.000283	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—TYMS—ovarian cancer	1.7e-05	0.000282	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	1.7e-05	0.000282	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.69e-05	0.000281	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.59e-05	0.000264	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—ABCB1—ovarian cancer	1.58e-05	0.000262	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—TYMS—ovarian cancer	1.56e-05	0.00026	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—TYMS—ovarian cancer	1.55e-05	0.000257	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—AKT1—ovarian cancer	1.47e-05	0.000244	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—FASN—ovarian cancer	1.39e-05	0.000231	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CAV1—ovarian cancer	1.37e-05	0.000228	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.37e-05	0.000227	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.32e-05	0.000219	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.31e-05	0.000217	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.26e-05	0.00021	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CAV1—ovarian cancer	1.26e-05	0.000209	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CAV1—ovarian cancer	1.25e-05	0.000207	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CG—ovarian cancer	1.25e-05	0.000207	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.19e-05	0.000198	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.15e-05	0.000191	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.14e-05	0.000189	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.12e-05	0.000186	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CD—ovarian cancer	1.1e-05	0.000182	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.04e-05	0.000173	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—TYMS—ovarian cancer	1.02e-05	0.00017	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.01e-05	0.000168	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1e-05	0.000166	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CB—ovarian cancer	9.56e-06	0.000159	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CB—ovarian cancer	8.79e-06	0.000146	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CB—ovarian cancer	8.72e-06	0.000145	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTEN—ovarian cancer	8.26e-06	0.000137	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CAV1—ovarian cancer	8.24e-06	0.000137	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTEN—ovarian cancer	7.6e-06	0.000126	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTEN—ovarian cancer	7.53e-06	0.000125	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CG—ovarian cancer	7.5e-06	0.000125	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CD—ovarian cancer	6.6e-06	0.00011	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CA—ovarian cancer	5.83e-06	9.68e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CB—ovarian cancer	5.75e-06	9.55e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CA—ovarian cancer	5.36e-06	8.91e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CA—ovarian cancer	5.32e-06	8.83e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTEN—ovarian cancer	4.97e-06	8.25e-05	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKT1—ovarian cancer	4.76e-06	7.91e-05	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKT1—ovarian cancer	4.38e-06	7.27e-05	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKT1—ovarian cancer	4.34e-06	7.21e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CA—ovarian cancer	3.51e-06	5.82e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKT1—ovarian cancer	2.86e-06	4.76e-05	CbGpPWpGaD
